Seattle Genetics Stock News

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management.

Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Sanofi SA (NASDAQ: SNY ) and Seagen Inc (NASDAQ: SGEN ) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi''s proprietary monoclonal antibody (mAb) technology and Seagen''s proprietary … Full story available on Benzinga.com

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Sanofi (SNY) and Seagen (SGEN) signed an exclusive collaboration agreement to develop and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.The…

BOTHELL, Wash. & PARIS--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has

Strategy of selecting 10 of 50 stocks, equally weighted, would have increased total return to 188.6%. Here we report most recent holdings and trading signals for 3/14/2021.

Seagen released mixed quarterly results and a weak outlook for 2022.

Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%.

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for

Astellas Worth A Look On Revenue Re-Acceleration Potential

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.